
    
      This is a study of 2 dose levels (0.16 or 0.64 mg/kg) of IMO-2055 administered by weekly
      subcutaneous (SC) injections in two patient populations, treatment na√Øve or previously
      treated patients. Each dose group (treatment naive or previously treated) will be randomized
      to receive one of the 2 doses being studied.
    
  